Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2009

Open Access 01-12-2009 | Research

Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats

Authors: Mostafa K El-Awady, Ashraf A Tabll, Yasmine S El-Abd, Hassan Yousif, Mohsen Hegab, Mohamed Reda, Reem El Shenawy, Rehab I Moustafa, Nabila Degheidy, Noha G Bader El Din

Published in: Virology Journal | Issue 1/2009

Login to get access

Abstract

The reason(s) why human antibodies raised against hepatitis C virus (HCV) E2 epitopes do not offer protection against multiple viral infections may be related to either genetic variations among viral strains particularly within the hypervariable region-1 (HVR-1), low titers of anti E2 antibodies or interference of non neutralizing antibodies with the function of neutralizing antibodies. This study was designed to assess the immunogenic properties of genetically conserved peptides derived from the C-terminal region of HVR-1 as potential therapeutic and/or prophylactic vaccines against HCV infection. Goats immunized with E2-conserved synthetic peptides termed p36 (a.a 430–446), p37(a.a 517–531) and p38 (a.a 412–419) generated high titers of anti-p36, anti-p37 and anti-P38 antibody responses of which only anti- p37 and anti- p38 were neutralizing to HCV particles in sera from patients infected predominantly with genotype 4a. On the other hand anti-p36 exhibited weak viral neutralization capacity on the same samples. Animals super-immunized with single epitopes generated 2 to 4.5 fold higher titers than similar antibodies produced in chronic HCV patients. Also the studied peptides elicited approximately 3 fold increase in cell proliferation of specific antibody-secreting peripheral blood mononuclear cells (PBMC) from immunized goats. These results indicate that, besides E1 derived peptide p35 (a.a 315–323) described previously by this laboratory, E2 conserved peptides p37 and p38 represent essential components of a candidate peptide vaccine against HCV infection.
Appendix
Available only for authorised users
Literature
1.
Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001, 345: 41-52. 10.1056/NEJM200107053450107CrossRefPubMed
2.
Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I: The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000, 355: 887-891. 10.1016/S0140-6736(99)06527-7CrossRefPubMed
3.
Strickland GT: Liver disease in Egypt: hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006, 43: 915-922. 10.1002/hep.21173CrossRefPubMed
4.
5.
Alter H: Discovery of non-A, non-B hepatitis and identification of its etiology. Am J Med 1999, 107: 16S-20. 10.1016/S0002-9343(99)00375-7CrossRefPubMed
6.
Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM: Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001, 34: 809-816. 10.1053/jhep.2001.27831CrossRefPubMed
7.
Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284: 450-56. 10.1001/jama.284.4.450CrossRefPubMed
8.
Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999, 340: 1228-1233. 10.1056/NEJM199904223401602CrossRefPubMed
9.
Wiese M, Grungreiff K, Guthoff W, Lafrenz M, Oesen U, Porst H: Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany – a 25-year multicenter study. J Hepatol 2005, 43: 590-598. 10.1016/j.jhep.2005.04.007CrossRefPubMed
10.
Ferenci P, Ferenci S, Datz C, Rezman I, Oberaigner W, Strauss R: Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s. J Hepatol 2007, 47: 31-36. 10.1016/j.jhep.2007.01.023CrossRefPubMed
11.
Manns MP, Wedemeyer H, Cornberg M: Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55: 1350-1359. 10.1136/gut.2005.076646PubMedCentralCrossRefPubMed
12.
13.
Pachiadakis I, Pollara G, Chain BM, Naoumov NV: Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infect Dis 2005,5(5):296-304. 10.1016/S1473-3099(05)70114-6CrossRefPubMed
14.
Phogat S, Wyatt RT, Karlsson GB: Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med 2007, 262: 26-43. 10.1111/j.1365-2796.2007.01820.xPubMedCentralCrossRefPubMed
15.
Heile JM, Fong YL, Rosa D, Berger K, Saletti G, Campagnoli S, Bensi G, Capo S, Coates S, Crawford K, Dong C, Wininger M, Baker G, Cousens L, Chien D, Ng P, Archangel P, Grandi G, Houghton M, Abrignani S: Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates. J Virol 2000, 74: 6885-6892. 10.1128/JVI.74.15.6885-6892.2000PubMedCentralCrossRefPubMed
16.
Martínez-Donato G, Capdesuñer Y, Acosta-Rivero N, Rodríguez A, Morales-Grillo J, Martínez E, González M, Alvarez-Obregon JC, Dueñas-Carrera S: Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice. Mol Biotechnol 2007, 35: 225-235. 10.1007/BF02686008CrossRefPubMed
17.
Abraham JD, Himoudi N, Kien F, Berland JL, Codran A, Bartosch B: Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins. Vaccine 2004, 22: 3917-3928. 10.1016/j.vaccine.2004.04.005CrossRefPubMed
18.
Majid AM, Ezelle H, Shah S, Barber GN: Evaluating replication defective vesicular stomatitis virus as a vaccine vehicle. J Virol 2006, 80: 6993-7008. 10.1128/JVI.00365-06PubMedCentralCrossRefPubMed
19.
Ma X, Forns X, Gutierrez R, Mushahwar IK, Wu T, Payette PJ, Bukh J, Purcell RH, Davis HL: DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpGoptimized vectors in mice. Vaccine 2002, 20: 3263-3271. 10.1016/S0264-410X(02)00304-3CrossRefPubMed
20.
Lechmann M, Liang TJ: Vaccine development for hepatitis C. Semin Liver Dis 2000, 20: 211-226. 10.1055/s-2000-9947CrossRefPubMed
21.
Fournillier A, Depla E, Karayiannis P, Vidalin O, Maertens G, Trépo C, Inchauspé G: Expression of noncovalent hepatitis C virus envelope E1–E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol 1999, 73: 7497-7504.PubMedCentralPubMed
22.
Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium K, Kuo C: Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994, 91: 1294-1298. 10.1073/pnas.91.4.1294PubMedCentralCrossRefPubMed
23.
Rosa C, Osborne S, Garetto F, Griva S, Rivella A, Calabresi G, Guaschino R, Bonelli F: Epitope mapping of the NS4 and NS5 gene products of hepatitis C virus and the use of a chimeric NS4–NS5 synthetic peptide for serodiagnosis. J Virol Methods 1995, 55: 219-232. 10.1016/0166-0934(95)00060-8CrossRefPubMed
24.
Youn JW, Park SH, Lavillette D, Cosset FL, Yang SH, Lee CG, Jin HT, Kim CM, Shata MT, Lee DH, Pfahler W, Prince AM, Sung YC: Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 2005, 42: 1429-1436. 10.1002/hep.20934CrossRefPubMed
25.
Puig M, Major ME, Mihalik K, Feinstone SM: Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 2007, 22: 991-1000. 10.1016/j.vaccine.2003.09.010CrossRef
26.
Christie JM, Healey CJ, Watson J, Wong VS, Duddridge M, Snowden N, Rosenberg WM, Fleming KA, Chapel H, Chapman RW: Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol 1997, 110: 4-8. 10.1111/j.1365-2249.1997.508-ce1412.xPubMedCentralCrossRefPubMed
27.
Chapel HM, Christie JM, Peach V, Chapman RW: Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 2001, 99: 320-324. 10.1006/clim.2001.5036CrossRefPubMed
28.
McKeating JA, Zhang LQ, Logvinoff C, Flint M, Zhang J, Yu J, Butera D, Ho DD, Dustin LB, Rice CM, Balfe P: Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virology 2004, 78: 8496-8505. 10.1128/JVI.78.16.8496-8505.2004PubMedCentralCrossRefPubMed
29.
Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, Kuo G, Spelbring JE, Meeks E, Sinha S, Carson DA: Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996, 173: 822-828.CrossRefPubMed
30.
Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP: Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008,134(5):1385-1395. 10.1053/j.gastro.2008.02.058CrossRefPubMed
31.
Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS: Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006,15;24(20):4343-4353. 10.1016/j.vaccine.2006.03.009CrossRef
32.
El Awady MK, El-Demellawy MA, Khalil SB, Galal D, Goueli SA: Synthetic peptide-based immunoassay as a supplemental test for HCV infection. Clin Chim Acta 2002,325(1–2):39-46. 10.1016/S0009-8981(02)00245-0CrossRefPubMed
33.
McKinney MM, Parkinson A: A simple, non-chromatographic procedure to purify immunoglobulins from serum and ascites fluid. J Immunol Methods 1987,11;96(2):271-278. 10.1016/0022-1759(87)90324-3CrossRef
34.
Nomura LE, deHaro ED, Martin LN, Maecker HT: Optimal preparation of rhesus macaque blood for cytokine flow cytometric analysis. Cytometry A 2003,53(1):28-38. 10.1002/cyto.a.10038CrossRefPubMed
35.
El-Awady MK, Tabll AA, Atef K, Yousef SS, Omran MH, El-Abd Y, Bader-Eldin NG, Salem AM, Zohny SF, El-Garf WT: Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro. World J Gastroenterol 2006,28; 12(16):2530-2535.
36.
Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, Ray SC, Thomas DL: Cross-genotype immunity to hepatitis C virus. J Virol 2004,78(3):1575-1581. 10.1128/JVI.78.3.1575-1581.2004PubMedCentralCrossRefPubMed
37.
Houghton M, Abrignani S: Prospects for a vaccine against the hepatitis C virus. Nature 2005,18; 436(7053):961-966. 10.1038/nature04081CrossRef
38.
Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42: 962-973. 10.1002/hep.20819CrossRefPubMed
39.
Kuiken C, Yusim K, Boykin L, Richardson R: The Los Alamos hepatitis C sequence database. Bioinformatics 2005, 21: 379-384. 10.1093/bioinformatics/bth485CrossRefPubMed
40.
von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, McKeating JA: Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007,132(2):667-678. 10.1053/j.gastro.2006.12.008CrossRefPubMed
41.
Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, Fong YL, Chien D, Abrignani S, Balfe P, Rice CM, McKeating JA, Houghton M: Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007,25(45):7773-7784. 10.1016/j.vaccine.2007.08.053CrossRefPubMed
42.
Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, Feinstone SM: Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA 2007,15;104(20):8449-8454. 10.1073/pnas.0703039104CrossRef
43.
Vietheer PT, Boo I, Drummer HE, Netter HJ: Immunizations with chimeric hepatitis B virus-like particles to induce potential antihepatitis C virus neutralizing antibodies. Antivir Ther 2007, 12: 477-487.PubMed
44.
Torresi J, Stock OM, Fischer AE, Grollo L, Drummer H, Boo I, Zeng W, Earnest-Silveira L, Jackson DC: A self-adjuvanting multiepitope immunogen that induces a broadly cross reactive antibody to hepatitis C virus. Hepatology 2007, 45: 911-920. 10.1002/hep.21538CrossRefPubMed
45.
Schofield DJ, Bartosch B, Shimizu YK, Allander T, Alter HJ, Emerson SU, Cosset FL, Purcell RH: Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 2005, 42: 1055-1062. 10.1002/hep.20906CrossRefPubMed
46.
Eren R, Landstein D, Terkieltaub D, Nussbaum O, Zauberman A, Ben-Porath J, Gopher J, Buchnick R, Kovjazin R, Rosenthal-Galili Z, Aviel S, Ilan E, Shoshany Y, Neville L, Waisman T, Ben-Moshe O, Kischitsky A, Foung SK, Keck ZY, Pappo O, Eid A, Jurim O, Zamir G, Galun E, Dagan S: Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J Virol 2006, 80: 2654-2664. 10.1128/JVI.80.6.2654-2664.2006PubMedCentralCrossRefPubMed
47.
Zhu LX, Liu J, Ye Y, Xie YH, Kong YY, Li GD, Wang Y: A candidate DNA vaccine elicits HCV specific humoral and cellular immune responses. World J Gastroenterol 2004,10(17):2488-2492.PubMedCentralCrossRefPubMed
Metadata
Title
Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats
Authors
Mostafa K El-Awady
Ashraf A Tabll
Yasmine S El-Abd
Hassan Yousif
Mohsen Hegab
Mohamed Reda
Reem El Shenawy
Rehab I Moustafa
Nabila Degheidy
Noha G Bader El Din
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2009
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-6-66

Other articles of this Issue 1/2009

Virology Journal 1/2009 Go to the issue

Research

Avian influenza virus (H5N1); effects of physico-chemical factors on its survival

Research

Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells

Research

Enhanced anti-HCV activity of interferon alpha 17 subtype

Research

Pathogenesis of aerosolized Eastern Equine Encephalitis virus infection in guinea pigs

Research

The role of mutations in core protein of hepatitis B virus in liver fibrosis

Research

Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits